These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 11485700)

  • 1. Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder?
    Hartnett NM; Saver BG
    J Fam Pract; 2001 Jul; 50(7):571. PubMed ID: 11485700
    [No Abstract]   [Full Text] [Related]  

  • 2. Detrol LA and Diropan XL for overactive bladder.
    Med Lett Drugs Ther; 2001 Apr; 43(1101):28. PubMed ID: 11283473
    [No Abstract]   [Full Text] [Related]  

  • 3. Anticholinergic drugs for overactive bladder.
    Kripke C
    Am Fam Physician; 2006 Jan; 73(1):66. PubMed ID: 16417066
    [No Abstract]   [Full Text] [Related]  

  • 4. RE: Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.
    Ellsworth P
    J Urol; 2003 Sep; 170(3):928; author reply 928. PubMed ID: 12913741
    [No Abstract]   [Full Text] [Related]  

  • 5. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
    Varadharajan S; Jumadilova Z; Girase P; Ollendorf DA
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S140-9. PubMed ID: 16161387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
    Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
    Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which anticholinergic drug for overactive bladder symptoms in adults.
    Hay-Smith J; Herbison P; Ellis G; Morris A
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005429. PubMed ID: 16034974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.
    Perfetto EM; Subedi P; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S150-7. PubMed ID: 16161388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder.
    Swift S; Garely A; Dimpfl T; Payne C;
    Int Urogynecol J Pelvic Floor Dysfunct; 2003 Feb; 14(1):50-4; discussion 54-5. PubMed ID: 12601517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Wein AJ
    J Urol; 2005 Jun; 173(6):2056-7. PubMed ID: 15879827
    [No Abstract]   [Full Text] [Related]  

  • 12. Persistence with overactive bladder pharmacotherapy in a Medicaid population.
    Shaya FT; Blume S; Gu A; Zyczynski T; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S121-9. PubMed ID: 16161385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial.
    Appell RA
    Curr Urol Rep; 2002 Oct; 3(5):343-4. PubMed ID: 12354340
    [No Abstract]   [Full Text] [Related]  

  • 14. POEMS (patient-oriented evidence that matters) spark discussion.
    Weiss BD
    J Fam Pract; 2001 Oct; 50(10):901. PubMed ID: 11674898
    [No Abstract]   [Full Text] [Related]  

  • 15. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
    Chu FM; Dmochowski RR; Lama DJ; Anderson RU; Sand PK
    Am J Obstet Gynecol; 2005 Jun; 192(6):1849-54; discussion 1854-5. PubMed ID: 15970828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment options for overactive bladder and incontinence.
    Newman DK
    Director; 2002; 10(3):74-6. PubMed ID: 12116753
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolterodine: a clinical review.
    Crandall C
    J Womens Health Gend Based Med; 2001 Oct; 10(8):735-43. PubMed ID: 11703885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical treatment of overactive bladder.
    Rackley R; Wein A; Nelson D
    Mayo Clin Proc; 2001 Nov; 76(11):1179-80. PubMed ID: 11702910
    [No Abstract]   [Full Text] [Related]  

  • 20. Is tolterodine (Detrol) or oxybutynin (Ditropan) the best for treatment of urge urinary incontinence?
    Blonski J
    J Fam Pract; 2001 Dec; 50(12):1017. PubMed ID: 11742595
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.